North America Immunosuppressant Drugs Market Size & Outlook
Related Markets
North America immunosuppressant drugs market highlights
- The North America immunosuppressant drugs market generated a revenue of USD 42,849.8 million in 2020.
- The market is expected to grow at a CAGR of 5.8% from 2021 to 2027.
- In terms of segment, monoclonal antibodies was the largest revenue generating drug class in 2020.
- Monoclonal Antibodies is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2021 to 2027.
North America data book summary
| Market revenue in 2020 | USD 42,849.8 million |
| Market revenue in 2027 | USD 63,618.9 million |
| Growth rate | 5.8% (CAGR from 2020 to 2027) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data covered | 2016 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Calcineurin Inhibitors, MTOR Inhibitors, Antiproliferative Agents, Monoclonal Antibodies |
Other key industry trends
- In terms of revenue, North America region accounted for 44.7% of the global immunosuppressant drugs market in 2020.
- Globally, North America is projected to lead the regional market in terms of revenue in 2027.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 33,976.8 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immunosuppressant Drugs Market Scope
Immunosuppressant Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| No records found. | ||||
North America immunosuppressant drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunosuppressant drugs market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 76.01% in 2020. Horizon Databook has segmented the North America immunosuppressant drugs market based on calcineurin inhibitors, mtor inhibitors, antiproliferative agents, monoclonal antibodies covering the revenue growth of each sub-segment from 2016 to 2027.
In March 2020, CDC issued guidelines for dental settings in response to the rising number of cases of COVID-19. As per the guidelines, dental settings were recommended to focus only on emergency & urgent visits and postpone all elective visits.
Guidelines by the various regulatory authorities are anticipated to facilitate safe delivery of dental care during the pandemic. According to the North American Dental Group survey, nearly 71% of the participants were unwilling to visit their dentist for nonemergency care due to the COVID 19 concerns.
Thus, fear psychosis coupled with financial issues related to equipment maintenance & facility rent during the lockdown is anticipated to lead to closure of several small dental offices. In addition, inadequate Personal Protective Equipment (PPE) in the region may also hinder growth.
Reasons to subscribe to North America immunosuppressant drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America immunosuppressant drugs market databook
-
Our clientele includes a mix of immunosuppressant drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America immunosuppressant drugs market, including forecasts for subscribers. This continent databook contains high-level insights into North America immunosuppressant drugs market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
North America immunosuppressant drugs market size, by country, 2016-2027 (US$M)
North America Immunosuppressant Drugs Market Share, 2020 & 2027 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
